Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
MER Indicator |
MER description |
Target Fiscal Year |
Target |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2016 |
650 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2016 |
673 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2016 |
3,773 |
CARE_CURR |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2016 |
7,768 |
CARE_CURR |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
12,864 |
CARE_CURR |
Sum of Aggregated Age/Sex disaggregates |
2016 |
12,864 |
CARE_NEW |
Aggregated Age/sex: <15 Female |
2016 |
30 |
CARE_NEW |
Aggregated Age/sex: <15 Male |
2016 |
62 |
CARE_NEW |
Aggregated Age/sex: 15+ Female |
2016 |
291 |
CARE_NEW |
Aggregated Age/sex: 15+ Male |
2016 |
655 |
CARE_NEW |
Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
1,038 |
CARE_NEW |
Sum of Aggregated Age/sex disaggregates |
2016 |
1,038 |
CARE_NEW |
Sum of Aggregated Age/sex disaggregates |
2016 |
1,038 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
2016 |
293 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
2016 |
293 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female |
2016 |
78,880 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2016 |
3,188 |
HTS_TST |
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
2016 |
7,420 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2016 |
15,803 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2016 |
86,886 |
HTS_TST |
Sum of Aggregated Age/Sex <15 |
2016 |
586 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2016 |
15,803 |
HTS_TST |
Sum of Aggregated Age/Sex 15+ |
2016 |
86,300 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2016 |
15,803 |
HTS_TST |
Sum of Aggregated Age/Sex disaggregates |
2016 |
86,886 |
KP_MAT |
Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months |
2016 |
1,050 |
KP_MAT |
Sex: Female |
2016 |
54 |
KP_MAT |
Sex: Male |
2016 |
996 |
KP_MAT |
Sum of Sex disaggregates |
2016 |
1,050 |
KP_PREV |
By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2016 |
5,191 |
KP_PREV |
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2016 |
280 |
KP_PREV |
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2016 |
5,264 |
KP_PREV |
By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2016 |
1,152 |
KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2016 |
11,886 |
LAB_CAP |
By clinical laboratories |
2016 |
12 |
LAB_CAP |
Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests |
2016 |
12 |
PMTCT_ARV |
Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) |
2016 |
594 |
PMTCT_ARV |
Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery |
2016 |
553 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy |
2016 |
222 |
PMTCT_ARV |
Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy |
2016 |
331 |
PMTCT_ARV |
Sum of New and Current disaggregates |
2016 |
553 |
PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2016 |
586 |
PMTCT_STAT |
By: Known positives at entry |
2016 |
451 |
PMTCT_STAT |
By: Number of new positives identified |
2016 |
143 |
PMTCT_STAT |
Number of new ANC and L&D clients |
2016 |
7,100 |
PMTCT_STAT |
Number of new ANC and L&D clients |
2016 |
124,700 |
PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2016 |
7,100 |
PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2016 |
124,700 |
PMTCT_STAT |
Sum of Positives Status disaggregates |
2016 |
594 |
TB_SCREEN |
Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 |
2016 |
1,295 |
TB_SCREEN |
Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ |
2016 |
11,313 |
TB_SCREEN |
Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load |
2016 |
12,864 |
TB_SCREEN |
Sum of Aggregated Age disaggregates |
2016 |
12,608 |
TB_SCREEN |
The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period |
2016 |
12,608 |
TX_CURR |
Aggregated Age/Sex: <1 Female |
2016 |
6 |
TX_CURR |
Aggregated Age/Sex: <1 Male |
2016 |
14 |
TX_CURR |
Aggregated Age/Sex: 15+ Female |
2016 |
3,625 |
TX_CURR |
Aggregated Age/Sex: 15+ Male |
2016 |
7,598 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2016 |
12,489 |
TX_CURR |
Sum of Aggregated Age/Sex (<1 and 1-14) <15 |
2016 |
1,266 |
TX_CURR |
Sum of Aggregated Age/Sex 15+ |
2016 |
11,223 |
TX_CURR |
Sum of Aggregated Age/Sex disaggregates |
2016 |
11,223 |
TX_NEW |
Aggregated Grouping by Age: <1 Male |
2016 |
14 |
TX_NEW |
Aggregated Grouping by Age/Sex: <1 Female |
2016 |
4 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Female |
2016 |
292 |
TX_NEW |
Aggregated Grouping by Age/Sex: 15+ Male |
2016 |
574 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2016 |
958 |
TX_NEW |
Sum of Aggregated Age/Sex disaggregates |
2016 |
866 |